- Total operating costs were reduced by more than 50% to SEK 38.3 million.
- R&D costs dropped to SEK 29.9 millionfrom SEK 63.7 million in 2020.The Company received a convertible loan of SEK 5.3 million from Östersjöstiftelsen. We expect the cash position of SEK 21.7 million at year-end to be sufficient to finance the phase IIa Tourette study.
FEBRUARY 11: Prof. Marco Bortolato (Univ. of Utah, USA) presents two sets of new preclinical data confirming that Sepranolone suppresses tics in Tourette Syndrome with no observable side-effects.
JUNE 8: The US Patent and Trademark Office grants a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and pathological gambling.
JUNE 23: Topline results from Asarina’s phase IIa study of Sepranolone for menstrual migraine find that a statistically significant difference compared to placebo was not obtained in the study’s primary and secondary endpoints.
SEPTEMBER 28: A post hoc analysis of Sepranolone for PMDD (Premenstrual Dysphoric Disorder) finds that Sepranolone in a 10 mg dose demonstrated a significant treatment effect compared to placebo, when examined in an extended 9-day analysis of symptom reduction. (The original study targeted a 5-day treatment period).
DECEMBER 22: Administrative approval of the two study sites for our phase IIa clinical study in Tourette syndrome was obtained following a five-month delay due to an administrative backlog in Copenhagen’s Region Hovedstaden city government.
To read the Report in full please visit: https://asarinapharma.com/investors/financial-reports/